# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Colin Bristow maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $25 to $4.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...
Cantor Fitzgerald analyst Li Watsek reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight.
Stifel analyst Bradley Canino reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $5...
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of...
Stifel analyst Bradley Canino maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $14...